Abstract
Growing evidence suggests that cell metabolism alterations represent a critical hallmark for majority of human cancer and tumors. One of the major differences between normal cells and cancer cells is relate to their growth and proliferation rate that require elevation in cell metabolism.
Cancer cells undergo several important specific metabolic reprogramming such as increased aerobic glycolysis, pH deregulation, enhanced level of reactive oxygen species (ROS) and lipid metabolism dysregulation (Neagu et al.; Stine et al.). Studying all of these cellular deregulations may lead to identification of therapeutic targets.
This special issue, presenting a compendium of eight articles, displays the role of metabolic reprogramming in development and progression of cancers, along with the underlying importance of metabolic compartmentalization within the cancer tissue. Furthermore, notable findings on early stage cancer diagnosis and novel drug targets in the broad domain of cancer metabolism are also presented as described below.